Imgatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Imgatuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from rat)
Target EGFR
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C6434H9942N1718O2016S44
Molar mass 145.0 kg/mol

Imgatuzumab (INN) is a humanized monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator.[1][2]

This drug was developed by Genentech/Roche.

References[edit]

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Imgatuzumab, American Medical Association.